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ABSTRACT  
Background: Following its first recognition in early 1960s, the increasing incidence of nosocomial and community-acquired 
methicillin resistant Staphylococcus aureus (MRSA) infections has become a global problem. The emergence of multiple-drug 
resistant MRSA strains and dissemination of epidemic antibiotic clones including presence of wide spectrum of virulence and 
predisposing risk factors complicate diagnosis, chemotherapy and control causing significant morbidity and mortality. 
Detection of MRSA strains in domestic animals and protozoan has widened the epidemiologic characters of the organism and 
may influence infection control policies.  
 
Objectives: To review the emergence and epidemiologic spread of resistant strains of MRSA, molecular/genetic basis of 
resistance in the organism and challenges facing control strategies worldwide. It also aims to suggest intervention strategies so 
as to checkmate the spread of MRSA infections.  
Methods: By reviewing local and international literatures on MRSA infections coupled with practical experience in the field of 
this endeavour.  
Result/Conclusion: MRSA has shown increasing endemic and epidemic spread in the last four decades causing serious medical 
and socio-economic difficulties. Routine and regular surveillance (uncommon in poor-resourced developing areas of especially 
sub-Saharan Africa), good hospital practices and personal hygiene, public enlightenment, development of effective therapeutic 
agents and rational administration of antibiotics based on reliable test results will limit the spread of MRSA infections.  
Key words: MRSA, incidence, morbidity, mortality, surveillance, control.  
 
INTRODUCTION  
Methicillin-resistant Staphylococcus aureus (MRSA) is 
an important bacterial pathogen causing nosocomial 
and community-onset infections which has shown 
increasing endemic and epidemic spread in the last 
four decades (1,2) ,while its control has become a 
serious concern worldwide (3,4). These MRSA 
associated infections impose a serous burden in terms 
of medical and socio-economic costs and cause 
significant morbidity and mortality (5-7).  
 
S. aureus (including MRSA strains) are cluster-
forming, facultative aerobic, Gram-positive cocci with 
intrinsic ability to ferment carbohydrates, producing 
white to deep yellow pigmentation on solid culture 
media. They also ferment mannitol turning Mannitol 
Salt Agar (MSA) yellow (8).  The organisms produce 
deoxyribonuclease (DNase) and catalase enzymes and 
coagulase proteins, often called enzymes (clumping  
factor) used for their identification. MRSA strains 
exhibit resistance to oxacillin or methicillin (1 or 
5µg/disk: zone of inhibition < 14mm in diameter 
used as marker for all β-lactams) and other 
antimicrobial agents (8,9)..  
 
MRSA has been severally shown to cause variety of 
diseases ranging from mild, superficial  
 
 
dermatological diseases to severe and potentially fatal 
systemic debilitations (10-11).  In spite of the 
availability of considerable number of effective 
antimicrobial chemotherapeutic agents, MRSA still 
remains an important and increasing cause of post-
surgical wound infections (12,13). some invasive 
infections such a nosocomial bacteremia and 
septicemia (sepsis) (14), acute endocarditis and 
osteomyelitis, pneumonia and other soft tissue 
infections (STIs),(13,15). The increasing prevalence of 
MRSA multiple-drug resistant strains which limits the 
therapeutic options available for the management of 
MRSA associated infections has become a worrisome 
issue worldwide (2). 
This paper aims to review the emergence and global 
epidemiologic spread of MRSA including multiple-
resistant strains, molecular/genetic basis of resistance 
in this organism and the challenges facing the control 
strategies worldwide. It also aims to suggest ways of 
overcoming these challenges in order to limit the 
spread of MRSA and associated health problems.  
 
Emergence and global epidemiological trend of 
MRSA  
Strains of MRSA were first detected in the United 
Kingdom (UK) in the early 1960s(16) soon after 
methicillin antibiotic was introduced for clinical use. 
During the next decade, the existence of MRSA 
strains was reported in the United States (US) with 
prevalence rate of less than 1%.(17) Since then, the 
endemic and epidemic outbreaks of the organism 
have been reported worldwide(18-20) but 
overwhelmingly from developed economies of the 
world. Presently, hospital of all sizes, other care 
centers, and increasing number of different 
population groups at various communities globally 
are facing the problem of MRSA infections (1,7,21).  
Reports emanating from different parts of the world 
revealed increasing rates in the incidence of MRSA 
and population at risk. The epidemiological data from 
north America including Center for Disease Control 
and Prevention (CDC) in the US showed that the 
prevalence of MRSA strains in both large and small 
hospitals located at different regions increased 
progressively over the years (21-25). Other studies 
conducted at various health care centers in the 
country revealed that out of all hospital bacterial 
isolates, the prevalence of MRSA, cumulatively 
increased from 6% in 1998 to 50% in 2002.(4) A similar 
study conducted earlier elsewhere in the country 
showed a 30% increase (from 20% to 50%) in MRSA 
prevalence within a two year period (i.e. from 1988 to 
1990) (26) . 
The published data from some countries of Europe 
and Asia presented identical scenario with significant 
increase in the outbreaks of MRSA infections. For 
instance, Mangeney and co-workers (27) documented 
MRSA prevalence of 33%-62% (in relation to S. aureus 
isolates) in their hospital wards in France. The report 
of De Sousa and colleagues (28) from Portugal though 
indicated downward trend in the outbreaks of MRSA 
infections but showed consistently high prevalence of 
MRSA during the last decade e.g. 65% in 1992; 49% 
and 47% in 1993 and 1994 respectively.  
In contrast, lower prevalence rates of MRSA have 
been reported in certain parts of Europe. For example, 
Harbath and co-researchers(29) reported 3% MRSA 
prevalence in their hospital in Geneva, Switzerland 
though further evidence showed that the MRSA were 
not nosocomial strains and could have originated 
from the community. In a similar study carried out in 
the UK,(30) the prevalence of MRSA was found to be 
comparatively low (<10%) but never the less 
significant in the population group studied. Identical 
scenario has been observed in Scandinavia and the 
Netherlands where incidence of MRSA appears 
relatively low compared to other European countries 
(31).  
 
In earlier studies carried out in Asia, a remarkable 
upsurge in MRSA prevalence has been documented 
in many areas, including Taiwan where an increase in 
MRSA prevalence from 4.3% in a period covering 
1981-1986 was reported  (32). In Japan (33) and 
Republic of Koria (34), MRSA prevalence of up to 54% 
and 70% have been  documented respectively. Both 
endemic and epidemic outbreaks have continued to 
rise in that region (35). On the other hand , reports 
from Africa on MRSA are scanty. Nonetheless, in 
study conducted in a  Khartoum hospital, Sudan, a 
prevalence of 11% was documented (36).  More so, the 
results of surveillance studies carried out by Kesah 
and other researchers (37) in some parts of Africa 
(including Lagos-Nigeria; Cameroon, Kenya and 
Algeria) and Malta between 1996 and 1997 revealed 
rates of 21 – 30% MRSA prevalence among the 
participating countries of the sub-Saharan region (e.g. 
Nigeria, Cameroon and Kenya) while that of North 
Africa (e.g. Algeria) and Malta presented lower rates 
of below 10%. However, results of similar studies 
carried out at different locations in Nigeria viz: Ilorin, 
(38) Calabar, (39) Jos, (40) (41) revealed higher MRSA 
prevalence rates of 34.7%, 36.4%, 43% and 49.1% 
respectively. More studies are clearly needed 
particularly in all regions of Africa including Nigeria 
and other developing poor-resourced areas to 
determine the current epidemiologic outlook of this 
increasingly important nosocomial and community-
acquired pathogen.  
 
Emergence of MRSA multiple antibiotic clones 
and public health implications According to Olive 
and Bean(42),  clonally related organisms are mostly 
members of the same species that share certain 
characteristics such as virulence factors, biochemical 
and genetic traits. These traits may aid the 
pathogenicity, resistance to drugs, or the critical 
mechanism for survival by the organism. They may 
also facilitate the general identification of such group 
of organisms Information from different 
geographical locations showed that clones, 
particularly the antibiotic types and those 
withinherent repertoires of virulence factors are 
spreading in various care centers, hospitals, among 
members of different sporting teams and in the 
communities (7, l1) that hitherto were not considered 
to be at risk of MRSA infections. Furthermore, MRSA 
strains have also been detected in domestic animals 
and birds such as horses, cattle, chickens and dogs as 
well as associated individuals (43,44). More so, a 
group of researchers in England has suggested that a 
protozoan, Acantha - amoeba polyphaga which is found 
virtually everywhere in the environment may aid the 
spread of MRSA. This is significant because other 
scientific evidence suggests that pathogens that 
emerge from amoebas may exhibit broader resistance 
to antibiotics and may be more virulent with serious 
epidemiologic and clinical implications (45). Data 
published by CDC (25) suggested that community - 
acquired MRSA (Ca - MRSA) is becoming more 
prevalent. Consequently, the array of virulence 
factors possessed by Ca-MRSA and broader resistance 
to antimicrobial agents being exhibited by the 
organism as compared to hospital - associated MRSA 
(Ha -MRSA) is of concern. Subsequently, Ca-MRSA 
had been implicated in various clinical conditions 
affecting some persons without any notable risk 
factors and in many cases the management of such 
conditions has resulted in poor prognosis (7). In 
addition, it has been proposed(3, 42, 46) that one clone 
with homogenous or heterogeneous resistance profile 
may be present in the same location at any given time 
thus compounding diagnostic problems (especially in 
poor - resourced areas) and treatment failures arising 
from empirical chemotherapy. The situation is even 
more compounded in patients with critical 
underlying ailments such as cancer, HIV/AIDS and 
those undergoing immunosuppressive therapy. Such 
conditions obviously constitute serious risk factors for 
MRSA infection and may results in severe 
complications and fatal consequences, especially if 
multiple - antibiotic resistant strains are involved.  
 
Molecular and genetic factors predisposing to 
antimicrobial resistance in MRSA  
It is now recognized that coding for methicillin 
resistance in MRSA is facilitated by the mec A gene, 
which is located on the staphylococcal cassette 
chromosome (SCC), a large mobile genetic element 
which differs in size and genetic composition among 
different strains of MRSA (4, 47). Consequently, at 
least five types of this organism have been classified 
accordingly (48-50) (Table I shows types I - IV as thus 
classified).  
The mechanism of resistance in this manner involves 
changes or defects brought about by mutation on mec 
A gene which result in modification to penicillin - 
binding protein 2a (PBP - 2a) product. The outcome 
of the event is that it renders the organism resistant to 
β-lactams and other antibiotics with the same target 
site. (4) In addition, other antibiotic resistance genes 
may be present in the cassette thus conferring on the 
organism, multiple - resistance to other antibiotics.(49)  
Apart from the inability of an antibiotic to bind to the 
target site due to structural defect of such site, other 
mechanisms that may generally play significant roles 
in the development of resistance in bacteria such as  
 
MRSA include efflux phenomenon (also a product of 
structural modification of cellular component e.g. cell 
wall/membrane protein) resulting in continuous 
pumping of antimicrobial drugs out of the bacterial 
cell. Others are alteration in the outer-membrane 
proteins which limit the access of drugs to the cell; 
resistance can also arise from high level production of 
β lactamase (51-53).  
On the other hand, PBP - mediated resistance in 
MRSA is suggested to take various forms and may 
arise from (a) overproduction of a PBP, (b) 
acquisition of a foreign PBP with low affinity, (c) 
recombination of susceptible PBP with more resistant 
varieties or (d) may be due to specific point 
mutations within PBPs that consequently lower their 
affinity for β lactams (10,53,54). Consequently, the 
occurrence of any of these events may lead to 
changes in antibiotic phenotypic characters of 
affected S. aureus strains. The classification of MRSA 
strains based on SCCmec present has notably 
revealed certain epidemiological features of these 
bacterial strains including possible sources of 
acquisition and dissemination (nosocomial versus 
community), nature of drug - resistance (single 
versus multiple), as well as genome characteristics 
viz: size of genome and type of ribosome found in 
individual strain type (Table 1). It is note worthy that 
type IV MRSA strains originating from the 
community (Ca-MRSA) were found to possess higher 
prevalence of certain virulence factors as compared 
with non methicillin - resistant S. aureus (NMRSA) 
and health care associated MRSA (Ha - MRSA). 
These factors include enterotoxin, Panton - Valentine 
leucocidin (PVL) e.g. as observed in USA 300 and 400 
strains, toxic shock syndrome toxin 1 (TSST-1), and 
other superantigens with serious clinical 
implications.(21,55,56) Consequently, the Ca- MRSA is 
believed to have inherent potential for greater disease 
than NMRSA, and broader antibiotic resistance than 
typical Ha – MRSA (57). The increasing prevalence of 
Ca-MRSA coupled with associated battery of 
virulence factors and wide spectrum of resistance to 
chemotherapeutic agents pose serious challenges for 
diagnosis, management and general control of MRSA 
infections. 
TABLE 1: CLASSIFICATION OF M RSA BASED ON SCCMEC-TYPE PRESENT (50,51) 
Type of SCCmec  Source        Resistance Genome Size (kb) Ribotype  
I Hospital Methicillin           34.3             Conserved  
             
I
I 
Hospital Multi-drug 53.0             Conserved  
III Hospital Multi-drug 66.9             Conserved  
IV Community Methicillin            21- 24           Variable  
Risk factors for the acquisition of MRSA  
Traditionally, MRSA is associated with health care 
institutions (11) following its first detection in the UK 
in the early 1960s (16).  However, though Ca - MRSA 
became prominent during the last decade 
nevertheless its extent in most communities is 
uncertain (36,57).  In addition, the frequency of Ca - 
MRSA infections among otherwise healthy persons 
without typical Ha - MRSA risk factors is increasing 
with concomitant health problems (58).  Reports of Ca 
- MRSA prevalence indicated high rates among 
certain population groups such as those living in 
close contact or proximity to one another such as 
prisons, barracks and care centres (11,21, 24). The 
presence of several risk factors (Table 2) , which 
increasingly predispose the general populace to 
MRSA infection is raising concern worldwide(2,7, 55).  
 
The above developments therefore constitute a 
challenge to the researchers in health sector, 
epidemiologists, policy makers and health care 
providers at all levels in the developing world to 
fashion out a coordinated effort at ascertaining the 
current epidemiologic profile in various communities 
and groups for necessary intervention programmes. 
On the other hand Ha - MRSA strains, are usually 
introduced into the health care institutions by either 
an infected or colonized health care worker (62). 
Several risk factors have been suggested for the 
acquisition of nosocomial MRSA. They include 
previous or excessive antimicrobial therapy (4), 
previous hospitalization (1), autoimmune diseases 
including immunosuppressive therapy as well as 
surgery and prolonged hospital stay (>8.4 days) (4). 
Others are enteral feeding, mechanical ventilation, 
implantation of prosthetic devices (63) and nasal 
carriage of MRSA (64).  
 
The increased use of indwelling devices coupled with 
increasing number of immunocompromised patients 
such as HIV/AIDS and cancer patients particularly in 
the developing countries of sub-Saharan Africa and 
parts of Asia compound the problem of control of 
MRSA. The existing control strategies have 
progressively been inundated by the massive increase 
in antibiotic use in the hospitals worldwide and in the 
communities (through self medication) especially in 
developing countries resulting in selective pressure 
and emergence of highly resistant MRSA strains. In 
addition, the recognition of several risk factors for 
MRSA infection and wide spectrum of resistant 
pattern to antimicrobial drugs by the organism clearly 
make effective control highly tasking and have been 
considered a global crisis (5,65). 
.                         
TABLE 2: RISK FACTORS FOR MRSA (57-60) 
Susceptibility patterns of MRSA and antibioticreatment of associated infections. 
• Direct contact with an infected or colonized individual  
• Crowded and unhygienic living conditions.  
• Recent long-term antibiotic use (within six months) or history of frequent antibiotic use.  
• Frequent antibiotic use or abuse (including suboptimal dose) for chronic problems such as otitis media, atopic dermatitis 
(or eczema) and pharyngitis.  
• Recent or frequent outpatient visits (including outpatient surgical procedures).  
• Injection or intravenous drug use and homosexuals.  
• Shared clothing and/or equipment and other items.  
• Underlying chronic illness (especially dermatologic diseases) and HIV/AIDS.  
• Contact with family member or household working in health care facility e.g. Nurses, Doctors, Laboratory scientists e.t.c.  
• Caretaker for person with unknown history of MRSA infections.  
• Participation in close contact sports such as wrestling, football e.t.c.  
• Contact with toiletries or bed linens of an infected individual.  
• Individuals living in close proximity and with frequent close contact such as prisons, dormitories, army barracks and 
child care settings.  
• Regular exposure to clinical specimens without adequate preventive measures (e.g. in hospital wards and laboratories). 
Various reports (4,5,16,30) have described high-level 
resistance of MRSA to antibiotics apart from 
methicillin as a common phenomenon. The reports 
further stated that in the developed economies of 
North America for instance, up to 90%, 95% and 83% of 
MRSA infections were resistant to fluoroquinolones, 
erythromycin and c1indamycin respectively. The 
organism has also expressed high level resistance to 
other antimicrobial agents like gentamycin (75-93%), 
ketolides (82-98%) and trimethoprim/sulfamethoxazole 
(16-65%) (Table 3). However, rates of resistance to 
some antibiotics, such as inducible c1indamycin was 
lower among methicillin-susceptible S. aureus than 
MRSA in some locations (2,6).  Certain drugs also 
were less effective against MRSA infections due to 
some factors and characteristic nature of such drugs. 
For example, vancomycin used to treat MRSA 
systemic infections was found to be less effective in 
the treatment of ventilator-associated pneumonia 
(VAP) due to its poor lung penetration unlike such 
drugs as linezolid with effective penetration of the 
body including tissue, muscle, fat and bone (57).  On 
the other hand, antibiotic susceptibility pattern of 
MRSA is not uniform or clear cut in the developing 
countries and thus varies from one geographical 
location to another depending on various factors 
(36,37-42).  
In view of this scenario the following factors are 
imperative for consideration in the selection of 
antibiotics for the treatment of MRSA infection. They 
include: (a) susceptibility of the organism to 
antibiotics (b) the type of infection (c) drug 
characteristics such as activity (i.e. bactericidal versus 
bacteriostatic) (d) mechanism of action (e) blood 
level/tissue penetration (f) toxicity (g) cost and 
availability (h) early initiation of appropriate 
antimicrobial chemotherapy is also essential for 
favourable prognosis and outcome (4,11).  
 
Antidote for increasing MRSA acquisition 
dissemination and spread  
In the developed countries of North America e.g. US 
and Canada, and parts of Europe, considerable  
 
attention has been given to infection control 
programme which has led to significant reduction in 
the incidence of many infectious diseases.(1,2) 
However, the situation in many developing regions 
of the world appears gloomy due to inadequate or 
poor implementation of policy on infection control 
due to lack of political will, inadequate resources 
including shortage or ill-equipped manpower, poor 
motivation of health care workers and researchers. 
Other militating factors include extreme poverty and 
ignorance on the part of the general populace. 
However, in order to bring the present situation 
under control, some holistic measures are imperative 
for strict implementation at local and national 
hospital levels, communities and corporate 
establishments involving health care workers, 
researchers, epidemiologists and drug anufacturers. 
These include:- (a) regular surveillance of endemic 
and epidemic outbreaks of MRSA especially in high 
risk centres, (b) screening before employment and 
periodic test of health care workers and identification 
of carrier status plus adequate treatment to eliminate 
potential source of infection,  
TABLE 3: RESISTANCE RATES OF MRSA STRAINS TO ANTIBIOTICS (4,15,32) 
       Antimicrobial agent           Rate of resistance (%) 
 * Erythromycin     90 – 95 
 * Gentamycin     75 – 93 
 * Fluoroquinolones    30 – 90* 
* Clindamycin     75 – 83 
* Ketolides     82 – 98 
* Tetracycline     18 – 82 
* Trimethoprim/sulfamethoxazole   16 – 65 
* Quinupristin/dalfopristin      4 – 31 
* Fusidic acid       5 – 10 
                                                                 * Vancomycin                  0 – 5 
                                                                 * Oxazolidinones (e.g. Linezolid)                0 – 1 
                                                                 * Tigecycline                                        0 
                                                                 * Daptomycin                        0 
*-variable in developing countries and may be lower in some cases 
 
(c) screening of high risk patients and other 
individuals, (d) routine laboratory diagnosis (which 
is lacking in most developing areas) and prompt 
identification of MRSA and determination of 
antibiotic susceptibility profile while (e) empirical 
treatment of MRSA infection should be based on 
prior determination of local resistance patterns. Other 
measures involve (f) the enforcement of good 
hospital practices, (g) provision and adequate 
implementation of educational programs on hospital, 
community and personal hygiene, and (h) 
development of effective chemotherapy to replace 
those drugs to which the organism has developed 
resistance. More so, rational administration of 
antibiotics based on rapid and reliable laboratory test 
results will go along way in reducing the cases of 
treatment failures, and selective pressure leading to 
the proliferation of MRSA resistant strains.  
CONCLUSION  
The increasing prevalence of MRSA infections in the 
hospitals, other care centres and lately in the 
community has become a worldwide phenomenon. 
The wide spread dissemination of multiple - drug 
resistant strains and antibiotic clones of the bacterium 
facilitated by inherent or acquired molecular/genetic 
element is worrying as it complicates diagnosis and 
chemotherapy. More so, the presence of wide array of 
virulence and potential risk and spreading factors 
compounds morbidity and control measures. There is 
need for adequate policy framework on infection 
control that will reflect the current realities on the 
epidemiologic characters of MRSA as well as strict 
implementation of such control program to 
checkmate the spread of MRSA infections.
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